About BioBlocks
BioBlocks is a Healthcare company based in San Diego (United States) founded in 2000, and was acquired by Genesis Biotechnology Group in October 2021. Medicinal chemistry services from initial lead discovery to identification of development candidates. The company has 3 employees. BioBlocks offers products and services including Medicinal Chemistry Services, Building Blocks, and Bioanalytical Services. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry. Its legal entity is BIOBLOCKS, INC.
Company details
BioBlocks provides products and services for medicinal chemistry. Their proprietary Leap-to-Lead drug discovery platform has three components - a Comprehensive Fragment Library (CFL - a proprietary next generation 3D library), Syntheverse library, (a virtual library of currently synthesizable compounds) and a fragment based lead discovery offering which includes identification of leads with high ligand efficiency and low molecular weight and SAR studies, among others. Their product portfolio includes unique drug-like building blocks and diverse chemotypes (which includes a comprehensive collection of (quinolines, beta amino acids, a diverse group of well functionalized heterocycles, kinase-targeted amines, natural product-derived scaffolds, among others). They have served as the chemistry department of a virtual biotech.
- Headquarters San Diego, United States
- Employees 3
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bioblocks.com
- Social LinkedIn
- Acquired by Genesis Biotechnology Group (Oct 2021)
- Legal Name Bioblocks, Inc.
- Latest Funding Round$57.2K (USD), Grant
Jan 2019
- InvestorsEuropean Union
& 2 more
- Employee Count3
- Acquired byGenesis Biotechnology Group
(Oct 2021)
Products & Services of BioBlocks
BioBlocks offers a comprehensive portfolio of products and services, including Medicinal Chemistry Services, Building Blocks, and Bioanalytical Services.
Provides chemistry expertise for drug optimization and synthesis.
Offers innovative drug-like compounds for pharmaceutical research.
Delivers testing for pharmacokinetics and pharmacodynamics in trials.
Funding Insights of BioBlocks
- Total Rounds 2
- Last Round Grant — $57,204
- First Round $58,318
(Aug 2018)
- Investors Count 2
All 2 funding rounds of BioBlocks with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2019 | $57,204 | Grant | – | – | |
| Aug 2018 | $58,318 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in BioBlocks
BioBlocks has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EIC Fund and Genesis Biotechnology Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
A consortium of companies focused on improving patient care. | genesisbiotechgroup.com | Hamilton, United States |
Investor details for BioBlocks
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioBlocks
4 dated milestones of BioBlocks across 21 years, from founding to its latest funding, stage changes and deals.
- Founded BioBlocks is founded.
- Funding First funding round of $58K.
- Funding Latest funding round, Grant, of $57K.
- Exit Acquired by Genesis Biotechnology Group.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as BioBlocks (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioblocks
Complete news archive for BioBlocks
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioBlocks
BioBlocks was founded in 2000 and raised its 1st funding round 18 years after it was founded.
BioBlocks is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
BioBlocks has 3 employees.
BioBlocks provides products and services for medicinal chemistry. Their proprietary Leap-to-Lead drug discovery platform has three components - a Comprehensive Fragment Library (CFL - a proprietary next generation 3D library), Syntheverse library, (a virtual library of currently synthesizable compounds) and a fragment based lead discovery offering which includes identification of leads with high ligand efficiency and low molecular weight and SAR studies, among others. Their product portfolio includes unique drug-like building blocks and diverse chemotypes (which includes a comprehensive collection of (quinolines, beta amino acids, a diverse group of well functionalized heterocycles, kinase-targeted amines, natural product-derived scaffolds, among others). They have served as the chemistry department of a virtual biotech.
BioBlocks offers Medicinal Chemistry Services, Building Blocks, and Bioanalytical Services.
BioBlocks has 3 investors. Key investors include European Union, EIC Fund, and Genesis Biotechnology Group.
BioBlocks operates through Bioblocks, Inc..
Yes. BioBlocks was acquired by Genesis Biotechnology Group in October 2021.